Savara Inc. Appoints Braden Parker as Chief Commercial Officer
Slice of Healthcare Team
Oct 02, 2024
Key Highlights
- Braden Parker appointed Chief Commercial Officer, effective immediately.
- Over 25 years of experience in biotech and healthcare, with a focus on rare disease products.
- Will lead Savara’s global commercial strategy for molgramostim in aPAP treatment.
- Former Chief Commercial Officer at Orchard Therapeutics, where he launched Libmeldy for metachromatic leukodystrophy.
- Molgramostim is in Phase 3 development and awaiting potential FDA approval.
Source: Business Wire
Notable Quotes
“ Braden is an accomplished leader with a proven track record of building commercial teams, leading successful rare disease product launches and accelerating growth for companies. ”
Matt Pauls, Chair and CEO at Savara
“ I believe molgramostim, if approved, is uniquely positioned to make a significant impact in the treatment of aPAP. ”
Braden Parker, Chief Commercial Officer at Savara
